SPDR S&P Health Care Equipment ETF (XHE)
- Previous Close
85.53 - Open
84.85 - Bid 84.89 x 1400
- Ask 85.07 x 1400
- Day's Range
84.78 - 85.25 - 52 Week Range
66.20 - 99.68 - Volume
4,592 - Avg. Volume
19,338 - Net Assets 255.96M
- NAV 85.49
- PE Ratio (TTM) 31.20
- Yield 0.03%
- YTD Daily Total Return 1.50%
- Beta (5Y Monthly) 1.16
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Health Care Equipment Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the health care equipment segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Health
Fund Category
255.96M
Net Assets
2011-01-26
Inception Date
Performance Overview: XHE
Trailing returns as of 6/7/2024. Category is Health.
People Also Watch
Holdings: XHE
Top 9 Holdings (19.87% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: XHE
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetASML: Raising Our Fair Value Estimate to EUR 900; TSMC Adopting High-NA EUV Earlier Than Expected
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice TargetBiogen Earnings: Encouraging Launches Point to Solid Growth Profile Beyond 2024
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetASML’s Weak Bookings Don’t Obscure Its Long-Term Potential; Raising Fair Value to EUR 790
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice Target